EligoChem

EligoChem designs, synthesises and markets compound libraries with good drug properties that access novel chemical space for use in Drug Discovery screening. EligoChem also provides library design and synthesis services to enable lead development into novel chemical space. EligoChem utilises a proprietary, unique and innovative approach to compound design to improve success rates in Drug Discovery.
The EligoChem directors each have over 25 years Medicinal Chemistry and Computational Chemistry experience with particular focus on parallel chemistry and state of the art library design and synthesis technologies to provide novel compound libraries and related services at a competitive price. Customers for Eligochem services include all Pharma, Biotech and Academic organisations who are screening for novel lead matter or optimising lead compounds in Drug Discovery programmes.

Aim of the business:

• Enhancing the success of drug discovery through providing compounds for screening as well as the effective utilisation of a unique and innovative drug design approach.
• Providing Medicinal Chemistry consultancy for both profit and non-profit research organisations to further enhance drug discovery.
• Engaging in innovative collaborative research.